Search Results - "Griffin, James D"

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader by Huang, Hai-Tsang, Dobrovolsky, Dennis, Paulk, Joshiawa, Yang, Guang, Weisberg, Ellen L, Doctor, Zainab M, Buckley, Dennis L, Cho, Joong-Heui, Ko, Eunhwa, Jang, Jaebong, Shi, Kun, Choi, Hwan Geun, Griffin, James D, Li, Ying, Treon, Steven P, Fischer, Eric S, Bradner, James E, Tan, Li, Gray, Nathanael S

“…Heterobifunctional molecules that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degradation represent an emerging pharmacological…”
Get more information

Inhibition of USP10 induces degradation of oncogenic FLT3 by Weisberg, Ellen L, Schauer, Nathan J, Yang, Jing, Lamberto, Ilaria, Doherty, Laura, Bhatt, Shruti, Nonami, Atsushi, Meng, Chengcheng, Letai, Anthony, Wright, Renee, Tiv, Hong, Gokhale, Prafulla C, Ritorto, Maria Stella, De Cesare, Virginia, Trost, Matthias, Christodoulou, Alexandra, Christie, Amanda, Weinstock, David M, Adamia, Sophia, Stone, Richard, Chauhan, Dharminder, Anderson, Kenneth C, Seo, Hyuk-Soo, Dhe-Paganon, Sirano, Sattler, Martin, Gray, Nathanael S, Griffin, James D, Buhrlage, Sara J

“…An inhibitor of the deubiquitinase (DUB) USP10 regulates the degradation of oncogenic FLT3, thus defining USP10 as a DUB for FLT3 and providing a therapeutic…”
Get full text

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors by Nelson, Erik A., Walker, Sarah R., Weisberg, Ellen, Bar-Natan, Michal, Barrett, Rosemary, Gashin, Laurie B., Terrell, Shariya, Klitgaard, Josephine L., Santo, Loredana, Addorio, Martha R., Ebert, Benjamin L., Griffin, James D., Frank, David A.

“…The transcription factor STAT5 is an essential mediator of the pathogenesis of chronic myelogenous leukemia (CML). In CML, the BCR/ABL fusion kinase causes the…”
Get full text

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL by Kantarjian, Hagop, Giles, Francis, Wunderle, Lydia, Bhalla, Kapil, O'Brien, Susan, Wassmann, Barbara, Tanaka, Chiaki, Manley, Paul, Rae, Patricia, Mietlowski, William, Bochinski, Kathy, Hochhaus, Andreas, Griffin, James D, Hoelzer, Dieter, Albitar, Maher, Dugan, Margaret, Cortes, Jorge, Alland, Leila, Ottmann, Oliver G

“…This phase 1 study treated 119 patients with imatinib-resistant chronic myelogenous leukemia (CML) with nilotinib, an inhibitor of BCR-ABL tyrosine kinase. The…”
Get full text

The roles of FLT3 in hematopoiesis and leukemia by Gilliland, D. Gary, Griffin, James D.

“…FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system…”
Get full text

Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy by Boytz, RuthMabel, Słabicki, Mikołaj, Ramaswamy, Sita, Patten, J. J., Zou, Charles, Meng, Chengcheng, Hurst, Brett L., Wang, Jinhua, Nowak, Radosław P., Yang, Priscilla L., Sattler, Martin, Stone, Richard M., Griffin, James D., Gray, Nathanael S., Gummuluru, Suryaram, Davey, Robert A., Weisberg, Ellen

“…Coronavirus disease 2019 (COVID‐19) remains a major public health concern, and vaccine unavailability, hesitancy, or failure underscore the need for discovery…”
Get full text

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia by Yoda, Akinori, Yoda, Yuka, Chiaretti, Sabina, Bar-Natan, Michal, Mani, Kartik, Rodig, Scott J, West, Nathan, Xiao, Yun, Brown, Jennifer R, Mitsiades, Constantine, Sattler, Martin, Kutok, Jeffrey L, DeAngelo, Daniel J, Wadleigh, Martha, Piciocchi, Alfonso, Dal Cin, Paola, Bradner, James E, Griffin, James D, Anderson, Kenneth C, Stone, Richard M, Ritz, Jerome, Foà, Robin, Aster, Jon C, Frank, David A, Weinstock, David M

“…The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets. We identified the…”
Get full text

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations by Garg, Swati, Ni, Wei, Griffin, James D., Sattler, Martin

“…Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy that is often associated with relapse and drug resistance after standard chemotherapy…”
Get full text

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor by Kim, Hyung-Gu, Tan, Li, Weisberg, Ellen L, Liu, Feiyang, Canning, Peter, Choi, Hwan Geun, Ezell, Scott A, Wu, Hong, Zhao, Zheng, Wang, Jinhua, Mandinova, Anna, Griffin, James D, Bullock, Alex N, Liu, Qingsong, Lee, Sam W, Gray, Nathanael S

“…The DDR1 receptor tyrosine kinase is activated by matrix collagens and has been implicated in numerous cellular functions such as proliferation,…”
Get full text

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl by Weisberg, Ellen, Manley, Paul W., Breitenstein, Werner, Brüggen, Josef, Cowan-Jacob, Sandra W., Ray, Arghya, Huntly, Brian, Fabbro, Doriano, Fendrich, Gabriele, Hall-Meyers, Elizabeth, Kung, Andrew L., Mestan, Jürgen, Daley, George Q., Callahan, Linda, Catley, Laurie, Cavazza, Cara, Mohammed, Azam, Neuberg, Donna, Wright, Renee D., Gilliland, D. Gary, Griffin, James D.

“…The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)…”
Get full text

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 by Weisberg, Ellen, Halilovic, Ensar, Cooke, Vesselina G, Nonami, Atsushi, Ren, Tao, Sanda, Takaomi, Simkin, Irene, Yuan, Jing, Antonakos, Brandon, Barys, Louise, Ito, Moriko, Stone, Richard, Galinsky, Ilene, Cowens, Kristen, Nelson, Erik, Sattler, Martin, Jeay, Sebastien, Wuerthner, Jens U, McDonough, Sean M, Wiesmann, Marion, Griffin, James D

“…The tumor suppressor p53 is a key regulator of apoptosis and functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2…”
Get full text

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma by Weisberg, Ellen, Chowdhury, Basudev, Meng, Chengcheng, Case, Abigail E., Ni, Wei, Garg, Swati, Sattler, Martin, Azab, Abdel Kareem, Sun, Jennifer, Muz, Barbara, Sanchez, Dana, Toure, Anthia, Stone, Richard M., Galinsky, Ilene, Winer, Eric, Gleim, Scott, Gkountela, Sofia, Kedves, Alexia, Harrington, Edmund, Abrams, Tinya, Zoller, Thomas, Vaupel, Andrea, Manley, Paul, Faller, Michael, Chung, BoYee, Chen, Xin, Busenhart, Philipp, Stephan, Christine, Calkins, Keith, Bonenfant, Debora, Thoma, Claudio R., Forrester, William, Griffin, James D.

“…Bromodomain-containing protein 9 (BRD9), an essential component of the SWI/SNF chromatin remodeling complex termed ncBAF, has been established as a therapeutic…”
Get full text

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2 by Xue, Yiying, Mei, Husheng, Chen, Yisa, Griffin, James D., Liu, Qingsong, Weisberg, Ellen, Yang, Jing

“…The coronavirus disease 2019 (COVID‐19) pandemic has affected a large portion of the global population, both physically and mentally. Current evidence suggests…”
Get full text

Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells by Chen, Jie, Li, Jian-Liang, Chen, Zirong, Griffin, James D, Wu, Lizi

“…Mucoepidermoid carcinoma (MEC) arises from multiple organs and accounts for the most common types of salivary gland malignancies. Currently, patients with…”
Get full text

Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells by Weisberg, Ellen, Ray, Arghya, Nelson, Erik, Adamia, Sophia, Barrett, Rosemary, Sattler, Martin, Zhang, Chengsheng, Daley, John F, Frank, David, Fox, Edward, Griffin, James D

“…Clinical responses achieved with FLT3 kinase inhibitors in acute myeloid leukemia (AML) are typically transient and partial. Thus, there is a need for…”
Get full text

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study by Ray, Arghya, Cowan-Jacob, Sandra W., Manley, Paul W., Mestan, Jürgen, Griffin, James D.

“…Patients with advanced stages of chronic myeloid leukemia (CML) often manifest imatinib mesylate resistance associated with point mutations in BCR-ABL. AMN107…”
Get full text

The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma by Chen, Zirong, Ni, Wei, Li, Jian-Liang, Lin, Shuibin, Zhou, Xin, Sun, Yuping, Li, Jennifer W, Leon, Marino E, Hurtado, Maria D, Zolotukhin, Sergei, Liu, Chen, Lu, Jianrong, Griffin, James D, Kaye, Frederic J, Wu, Lizi

“…No effective systemic treatment is available for patients with unresectable, recurrent, or metastatic mucoepidermoid carcinoma (MEC), the most common salivary…”
Get full text

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412 by Weisberg, Ellen, Boulton, Christina, Kelly, Louise M, Manley, Paul, Fabbro, Doriano, Meyer, Thomas, Gilliland, D.Gary, Griffin, James D

“…Constitutively activating FLT3 receptor mutations have been found in 35% of patients with acute myeloblastic leukemia (AML). Here we report the identification…”
Get full text

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML by Weisberg, Ellen, Barrett, Rosemary, Liu, Qingsong, Stone, Richard, Gray, Nathanael, Griffin, James D

“…Abstract An appealing therapeutic target in AML is constitutively activated, mutant FLT3, which is expressed in a subpopulation of AML patients and is…”
Get full text

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412 by Growney, Joseph D., Clark, Jennifer J., Adelsperger, Jennifer, Stone, Richard, Fabbro, Doriano, Griffin, James D., Gilliland, D. Gary

“…Constitutively activated forms of the transmembrane receptor tyrosine kinase c-KIT have been associated with systemic mast cell disease, acute myeloid…”
Get full text